glutamic acid has been researched along with Pituitary Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abedalthagafi, M; Barker, FG; Brastianos, PK; Cahill, DP; Curry, WT; Dunn, IF; Frederick, DT; Getz, G; Gill, CM; Jones, PS; Louis, DN; Nahed, BV; Nayyar, N; Panka, DJ; Romero, JM; Santagata, S; Shankar, GM; Sullivan, RJ; Taylor-Weiner, A | 1 |
| Brastianos, PK; Santagata, S | 1 |
1 review(s) available for glutamic acid and Pituitary Neoplasms
| Article | Year |
|---|---|
ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma.
Topics: Carcinoma, Papillary; Clinical Trials, Phase II as Topic; Craniopharyngioma; Endocrine Gland Neoplasms; Glutamic Acid; Humans; MAP Kinase Signaling System; Pituitary Neoplasms; Point Mutation; Proto-Oncogene Proteins B-raf; Valine | 2016 |
1 other study(ies) available for glutamic acid and Pituitary Neoplasms
| Article | Year |
|---|---|
Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Craniopharyngioma; Craniotomy; Cytoreduction Surgical Procedures; Drug Administration Schedule; Glutamic Acid; Humans; Imidazoles; Magnetic Resonance Imaging; Male; Molecular Targeted Therapy; Mutation; Neoplasm Recurrence, Local; Neoplasm, Residual; Oximes; Pituitary Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Treatment Outcome; Valine | 2016 |